Compare Kroger Co (KR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Twist Bioscience Corp — how do they compare? Kroger Co trades at $61.64 (market cap $36.27B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Kroger Co is far larger — about 3.6× Twist Bioscience Corp's market cap, and Kroger Co pays a 2.54% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and Twist Bioscience Corp for 27 Days on average.
| KR | TWST | |
|---|---|---|
Market Cap | $36.27B | $10.08B |
Volume | 8,301,523 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $205.00 |
52-Week Low | $55.53 | $25.45 |
Typical Hold Time | 108 Days | 27 Days |
Enterprise Value | $57.69B | $10.01B |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.64, up 4.03% today, with a bullish technical signal supported by moving averages. The stock shows mixed fundamentals with a low P/S ratio of 0.26 but elevated P/E of 33.19, while recent earnings beat expectations in two of the last three quarters. Analyst consensus is moderately bullish with a $70.62 price target, representing 14.6% upside potential from current levels.
Kroger offers value through its low valuation multiples and consistent dividends, but faces headwinds from competitive pressures and integration risks from pending acquisitions. The company's digital growth initiatives and retail media expansion provide growth catalysts, though margin compression remains a concern amid rising costs and softer sales guidance for fiscal 2026.
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
